Format

Send to

Choose Destination
J Clin Oncol. 2017 Sep 1;35(25):2863-2865. doi: 10.1200/JCO.2017.73.1331. Epub 2017 May 19.

Minimal Residual Disease Negativity Is a New End Point of Myeloma Therapy.

Author information

1
Jean-Luc Harousseau, Groupe Confluent, Nantes, France; and Herve Avet-Loiseau, Institut Universitaire du Cancer Oncopole, Toulouse, France.
PMID:
28525304
DOI:
10.1200/JCO.2017.73.1331

Supplemental Content

Full text links

Icon for Atypon
Loading ...
Support Center